|
Session 107-Poster Abstracts
Resistance to Integrase Inhibitors
Friday, 2-4 pm; Poster Hall |
554
 |
Resistance-associated Mutations to Integrase Inhibitor S/GSK1349572 in HIV-1 Integrase Inhibitor-naive and Raltegravir-experienced Patients
Anne-Genevieve Marcelin*1, I Malet1, L Fabeni2, D Armenia2, S Fourati1, B Masquelier3, C Katlama1, C F Perno2, V Calvez1, and F Ceccherini-Silberstein2
1INSERM U943, Hosp Pitie-Salpetriere, Univ Pierre et Marie Curie, Paris, France; 2Univ of Rome Tor Vergata, Italy; and 3Hosp Bordeaux, France |
555
|
S/GSK1349572 Is a Potent Next Generation HIV Integrase Inhibitor and Demonstrates a Superior Resistance Profile Substantiated with 60 Integrase Mutant Molecular Clones
Takahiro Seki*1, M Kobayashi1, C Wakasa-Morimoto1, T Yoshinaga1, A Sato1, T Fujiwara1, M Underwood2, E Garvey2, and B Johns2
1Shionogi & Co, Ltd, Osaka, Japan and 2GlaxoSmithKline, Research Triangle Park, NC, US |
| 556 |
Comparison of Raltegravir Susceptible and Resistant Viruses Define the Contribution of Secondary Mutations to Reductions in Raltegravir Susceptibility
Signe Fransen*, A Frantzell, S Gupta, C Petropoulos, and W Huang
Monogram Biosci, Inc, South San Francisco, CA, US |
557
|
Short-term RAL Monotherapy Does Not Predispose Patients to Develop RAL Resistance during Subsequent Combination Therapy: Analysis of Samples from Protocol 004
Michael Miller*, R Barnard, M Witmer, J Zhao, B-Y Nguyen, H Teppler, D Hazuda, and Protocol 004 Study Team
Merck & Co, Inc, West Point, PA, US |
558
|
Raltegravir Genetic Resistance Patterns in HIV-2 Infected Patients Failing Raltegravir-containing Regimen
B Roquebert1, S Matheron1, A Benard2, J Leleu1, R Tubiana3, M Karmochkine4, G Chene2, F Damond1, F Brun-Vezinet1, Diane Descamps*1, and on behalf the French HIV-2 ANRS Cohort CO5
1Hosp Bichat Claude Bernard, Paris, France; 2INSERM U897, Univ Victor Segalen Bordeaux 2, France; 3Hosp Pitie-Salpetriere, Paris, France; and 4European Hosp Georges Pompidou, Paris, France |
|
